Vol 6, No 2 (2009)


Efficacy of metoprolol in treatment and preventive of cardiovascular diseases

Chazova I.E., Ratova L.G., Ratova L.G., Chazova I.E.
Systemic Hypertension. 2009;6(2):4-7
pages 4-7 views

Amlodipin in the treatment of arterial hypertension

Galyavich A.S.
Systemic Hypertension. 2009;6(2):7-10
pages 7-10 views

Perindopril in treatment of patients with arterial hypertension and high cardiovascular risk

Недогода С.В., Nedogoda S.V.
Systemic Hypertension. 2009;6(2):10-15
pages 10-15 views

Obstructive sleep apnea syndrome

Litvin A.Y., Chazova I.E.
Systemic Hypertension. 2009;6(2):15-21
pages 15-21 views

The intensive control of blood pressure: possibilities of the combined therapy.

Andrushchishina T.B., Morozova T.E.
Systemic Hypertension. 2009;6(2):22-27
pages 22-27 views

Arterial hypertension and sleep apnea in pediatrics: results of pilot trial

Madaeva I.M., Shevyrtalova O.N., Dolgikh V.V., Madaeva I.M., Shevyrtalova O.N., Dolgich V.V.
Systemic Hypertension. 2009;6(2):28-31
pages 28-31 views

Combined low-dose therapy of arterial hypertension

Stryuk R.I.
Systemic Hypertension. 2009;6(2):31-34
pages 31-34 views
pages 34-38 views

Perspectives of using angiotensin receptor antagonists

Fomin V.V.
Systemic Hypertension. 2009;6(2):38-43
pages 38-43 views
pages 44-45 views

Vozmozhnosti telmisartana v ANGIO- i KArdioprotektsii i uluchshenii pokazateley uglevodnogo obmena pri narushenii tolerantnosti k glyukoze

Nedogoda S.V., Barykina I.N., Brel' U.A., Chalyabi T.A., Mazina G.V., Podol'skaya E.V., Ledyaeva A.A.
Systemic Hypertension. 2009;6(2):47-50
pages 47-50 views

The level of uric acid and its role at early stages of essential hypertension

Oshchepkova E.V., Dmitriev V.A., Polovitkina O.V., Titov V.N.


Aim: correlation of uric acid (UA) level on serum blood and urine with indicators of not specific inflammation and clinical characteristic in essential hypertension (EH) patients. Methods: 67 patients with EH (48 men) 30-65 years age (442) with stage 1 EH (n=37) and 2 (n=30) with moderate or high cardiovascular (CV) risk. The control group - 14 healthy peoples: (6 men) 45,52,1 years age with normal blood pressure (BP). The normal level of С-reactive protein (CRP) is less 3 mg/l. The normal level of UA in blood is 202,3-416,5 mkmol/l, and in urine is 1,48-4,43 mmol/24 hour. The estimates of creatinine clearance by the Cockroft-Gault formula. Results: the patients with EH have bigger level CRP, UA in blood and urine than healthy peoples with normal BP. Higher levels UA in blood and urine have patients even with early stages EH and moderate CV risk. The bigger level of UA in blood has EH patients with obesity and dyslipidaemia. The level of UA in blood and urine is higher at EH patients with hyperfiltration vs patients with normal creatinine clearance. Conclusion: the patients with early stage of EH have higher level of UA in blood and urine than healthy peoples with normal BP. The level of UA in blood and urine is correlated with dyslipidaemia. Key words: essential hypertension, uric acid, non specific inflammation
Systemic Hypertension. 2009;6(2):51-56
pages 51-56 views

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies